Wednesday, July 20, 2011

Lack of sperm coating plays role in infertility (AP)

WASHINGTON � Scientists have found a new contributor to male infertility, a protein that's supposed to coat sperm to help them swim to an egg, unless that coating goes missing.

About 20 percent of men may harbor gene mutations that leave their sperm coat-free and thus lower their fertility, an international research team reported Wednesday.

Today's reproductive tests can't spot the problem, said study co-author Dr. Theodore Tollner of the University of California, Davis.

"You would have no reason to think many of these men with the genetic mutation would have reduced sperm function," he said.

Anywhere from 10 percent to 15 percent of couples experience infertility, and doctors can't always find the cause. A lack of sperm or problems with their shape or ability to move explains only a fraction of infertility.

The California-led team found a new reason, a protein that's part of a family of germ-killing molecules found on the surfaces of a variety of tissues. It's secreted as sperm journey into the female reproductive tract, helping the sperm to penetrate the mucus in a woman's cervix and to avoid being tagged as an invader by her immune system.

Having two copies of a particular gene mutation means sperm cannot produce that coating. Lab tests show those sperm have a hard time making it through the mucus.

But how much does that affect fertility?

The researchers tracked 500 newly married Chinese couples attempting to conceive. The birth rate was 30 percent lower among couples with a husband who harbored that double mutation, scientists reported in the journal Science Translational Medicine.

Having just one copy of the mutated gene doesn't seem to hinder conception.

The coatless sperm don't always fail, so it's not clear just how much this issue contributes to male infertility overall.

But creating a test to diagnose these men would be easy, the researchers said. Such a test potentially would lessen the time that a couple having problems conceiving spends in limbo before trying treatments such as having sperm placed directly into the woman's uterus.

One day, a vaginal gel might even let sperm pick up the protein coating as it travels into the cervix. The California researchers say they're already trying that with animals.



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

CDC: Frogs tied to salmonella being sold again (AP)

ATLANTA � A California company has resumed selling a kind of pet frog that caused salmonella illnesses in more than 240 people, most of them children. And federal health officials are not happy.

Centers for Disease Control and Prevention officials on Wednesday warned consumers that Blue Lobster Farms in June had resumed shipping African dwarf frogs from its Madera County, California, breeding facility. They say the frogs may still pose a serious health risk.

The company voluntarily stopped shipping the frogs in April, after an investigation fingered them as the source of a salmonella outbreak that sickened people nationwide over two years. No one died, but many illnesses were in children under 5 years old � some hospitalized.

Company officials could not be reached for comment.

___

http://www.cdc.gov/salmonella/water-frogs-0411/

http://www.cdc.gov/media/matte/2011/05_waterfrogs.pdf



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

Progress is seen on a blood test for Alzheimer's (AP)

PARIS � Scientists are closing in on a long-sought goal: A blood test to screen people for Alzheimer's disease.

An experimental test did a good job of indicating how much of the telltale Alzheimer's plaque lurks in people's brains, Australian researchers reported Wednesday. If the test proves accurate in larger studies, it could offer a way to check people having memory problems to see who needs more definitive testing for the disease.

Many blood tests are being developed and a few are used in research settings now, but only the Australian one has been validated against brain scans and other accepted diagnostic tests with good accuracy in large groups of people, said Maria Carrillo, senior director of medical and scientific relations for the Alzheimer's Association.

The results, reported Wednesday at the Alzheimer's Association International Conference in France, "give us hope that we may be able to use a blood test in the near future," although that doesn't mean next year, she said.

More than 5.4 million Americans and 35 million people worldwide have Alzheimer's, the most common form of dementia. It has no cure and drugs only temporarily ease symptoms. Finding it early allows patients and their families to prepare, and ruling it out could lead to diagnosing a more treatable cause of symptoms, such as sleep problems.

Brain scans can show signs of Alzheimer's � sticky clumps of a protein called beta amyloid � a decade or more before it causes memory and thinking problems, but scans are too expensive and impractical for routine use. Doctors and patients need simple ways to screen people for the disease.

Samantha Burnham and others at Australia's national science agency, CSIRO, working with several universities, used a long-running study of more than 1,100 people � some healthy, some impaired � to develop the blood test.

They started with blood samples from 273 study participants and identified nine hormones and proteins that seemed most predictive of amyloid levels in the brain. A cutoff level was set for what was considered high.

"The belief is that people above that point will go on to get Alzheimer's disease, and the lag is about 8 to 10 years," Burnham explained.

When researchers used the nine-marker blood test on these same participants, they found that it separated healthy people from those with mild cognitive impairment or Alzheimer's as verified by their brain scans. The test correctly identified 83 percent of people with high amyloid levels and correctly ruled out 85 percent of people without this condition.

"That's pretty high," the Alzheimer's Association's Carrillo said of the test's accuracy.

More importantly, she said, the Australian researchers validated the test's accuracy in two additional groups: the other 817 folks in the Australian study and 74 people in a big U.S.-led study aimed at finding novel Alzheimer's disease biomarkers.

The test performed well in those situations, too, Burnham said.

CSIRO has patented the test and is talking with major companies about making it commercially available.

"It sounds like the Australians do have good clinical data" and that the markers they are testing for track with cases of the disease, said Creighton Phelps, a neuroscientist with the U.S. National Institute on Aging.

The next step is wider validation work and ensuring it can be standardized to give reliable results regardless of what lab or doctor would use it, he said.

___

Online:

National Institute on Aging: http://www.nia.nih.gov/Alzheimers

Alzheimer's Association: http://www.alz.org

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP



Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials